Is NSF only the tip of the “gadolinium toxicity” iceberg?
Open Access
- 29 July 2008
- journal article
- editorial
- Published by Wiley in Journal of Magnetic Resonance Imaging
- Vol. 28 (2), 284-286
- https://doi.org/10.1002/jmri.21478
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Tissue distribution and kinetics of gadolinium and nephrogenic systemic fibrosisEuropean Journal of Radiology, 2008
- Extracellular Gd-CA: Differences in prevalence of NSFEuropean Journal of Radiology, 2008
- Magnetic resonance angiography (MRA) in renally impaired patients: When and howEuropean Journal of Radiology, 2008
- NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Nephrogenic Systemic Fibrosis Risk: Is There a Difference between Gadolinium‐Based Contrast Agents?Seminars in Dialysis, 2008
- Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosisBritish Journal of Dermatology, 2007
- Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamideEuropean Radiology, 2006
- Comparison of Gd(DTPA-BMA) (Omniscan) Versus Gd(HP-DO3A) (ProHance) Relative to Gadolinium Retention in Human Bone Tissue by Inductively Coupled Plasma Mass SpectroscopyInvestigative Radiology, 2006
- The Synthesis and Evaluation of Macrocyclic Gadolinium-DTPA-bis (amide) Complexes as Magnetic Resonance Imaging Contrast AgentsInvestigative Radiology, 1994
- Preclinical Safety Assessment and Pharmacokinetics of Gadodiamide Injection, a New Magnetic Resonance Imaging Contrast AgentInvestigative Radiology, 1993
- The relationship between thermodynamics and the toxicity of gadolinium complexesMagnetic Resonance Imaging, 1990